2.54k followers • 21 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks that were removed from most watchlists by Yahoo Finance Users. This list is generated daily and limited to the top 30 stocks that meet the criteria.
Gilead Sciences, Inc.
Ross Stores, Inc.
Fiat Chrysler Automobiles N.V.
Teva Pharmaceutical Industries Limited
Medical Properties Trust, Inc.
Newell Brands Inc.
Canopy Growth Corporation
EQM Midstream Partners, LP
AVITA Therapeutics, Inc.
Amarin Corporation plc
Cronos Group Inc.
Canopy Growth Corporation (CGC) closed at $16.02 in the latest trading session, marking a -1.9% move from the prior day.
EPR Properties (NYSE: EPR) will release second quarter 2020 financial results August 5 and host a management conference call August 6 at 8:30 ET.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter financial results on Wednesday August 5, 2020 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schlumberger (SLB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is (ABT) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries
Gilead (GILD) begins a phase I study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir for coronavirus.
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today preliminary unaudited results for the fourth quarter and full year ended June 30, 2020, together with a company update.
Gilead Sciences Inc <GILD.O> plans to make more of its drug remdesivir available for Germany and Europe from autumn and will decide how much each country gets based on the rate of infection, the drugmaker's Germany boss told a German magazine. Bettina Bauer, managing director of Gilead in Germany, told WirtschaftsWoche the U.S. drugmaker can increase its worldwide monthly production from currently 190,000 treatment cycles to 2 million treatment cycles in December.
A federal judge on Wednesday threw out a racketeering lawsuit General Motors Co had filed against smaller rival Fiat Chrysler Automobiles NV, saying the No. 1 U.S. automaker's alleged injuries were not caused by FCA's alleged violations. GM officials said in statement they "strongly disagree" with the order by U.S. District Court Judge Paul Borman, whom the automaker had sought to have removed from the case, and would appeal. "There is more than enough evidence from the guilty pleas of former FCA executives to conclude that the company engaged in racketeering, our complaint was timely and showed in detail how their multi-million dollar bribes caused direct harm to GM," GM said in a statement.
The company said the trial, which will enroll about 60 healthy Americans aged between 18 and 45, will test the drug particularly in those cases where the disease has not progressed to require hospitalization. The drug is currently used intravenously and an inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside hospitals. Remdesivir was granted emergency use authorization in the United States to treat severe cases of COVID-19 in patients who are hospitalized.
The pharma stock collapsed on the threat of generic competition for a drug that launched in December 2019, but the move may have been a bit of an overreaction.
It pays to check the valuation before investing because it isn't always the best companies that have upside potential.
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.
Both cannabis markets are drawing attention. How are these two companies approaching these segments?
Tenneco Inc. (NYSE: TEN) announced that its board of directors has appointed Mr. Kevin Baird as chief operating officer, effective August 3, 2020. In this role, Mr. Baird joins the executive leadership team and will lead and support critical strategic and operations initiatives that deliver margin expansion and cash generation improvements.
Readers hoping to buy Oracle Corporation (NYSE:ORCL) for its dividend will need to make their move shortly, as the...
TORONTO, July 09, 2020 -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) announces that, effective today, the Company has continued from the.
Tenneco Inc. (NYSE: TEN) announced that its board of directors has appointed Matti Masanovich as chief financial officer, effective August 10, 2020. He will succeed interim CFO Ken Trammell.
Bellwether health care stocks Johnson & Johnson and Abbott Laboratories are widely expected to report earnings crashes next Thursday and declining sales amid the coronavirus pandemic.
The Lawrence J. Ellison Institute for Transformative Medicine of USC ("Ellison Institute") and Oracle reveal a promising two-step technique to train a high-confidence predictive algorithm for enhanced cancer diagnostics. The study uses novel tissue "fingerprints"—discriminating microscopic hematoxylin and eosin (H&E;) histologic features—of tumors paired with correct diagnoses to facilitate deep learning in the classification of breast cancer ER/PR/HER2 status.